Home » Topics » Cardiovascular, BioWorld Science

Cardiovascular, BioWorld Science
RSS

Topline results presented from phase I/II study of ITI-214 heart failure

June 30, 2020

Korea Research Institute of Chemical Technology patents PDE9A inhibitors

June 30, 2020

Positive data from phase III RHAPSODY study of rilonacept in recurrent pericarditis

June 30, 2020

Imperial College of Science, Technology and Medicine discloses MAP4K4 inhibitors

June 26, 2020

VP-01 demonstrates significant benefit in preclinical model of severe pulmonary hypertension

June 23, 2020

Serum EMC10 is tied to atherosclerosis and coronary artery disease

June 22, 2020

Bristol-Myers Squibb patents FPR1/FPR2 agonists

June 19, 2020

Bayer initiates phase III FINEARTS-HF study of finerenone in heart failure

June 16, 2020

Black Belt TX patents arginase inhibitors

June 10, 2020

Type-1 angiotensin II receptor antagonists discovered at MFC

June 5, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...